This article is a collaboration between 51˶ and:
CHICAGO -- What role should ezetimibe (Zetia), niacin, and other nonstatin strategies play in managing LDL cholesterol? A new from the American College of Cardiology recommends a pathway for making the decision with patients.
Discussing the document in this video are:
- , of Baylor College of Medicine in Houston
- , of Florida Atlantic University in Boca Raton
- , of the University of Iowa in Iowa City
- , of Northwestern Memorial Hospital in Chicago
- , of NYU-Langone Medical Center in New York City
The document was published in the Journal of the American College of Cardiology and presented here at the organization's conference.
Primary Source
Journal of the American College of Cardiology
Lloyd-Jones DM, et al "2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol Lowering in the management of atherosclerotic cardiovascular disease risk: a report of the american college of cardiology task force on clinical expert consensus documents" J Am Coll Cardiol 2016; DOI: 10.1016/j.jacc.2016.03.519.